secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-067061
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Q1 revenue $17.4M, cash $249M; restructures to focus on next-gen ADCs, headcount cut ~50%
--------------------------------------------------------------------------------

- Revenue of $17.4M vs $13.0M Q1 2024; cash $249M down from $316.9M Dec 2024; runway into early 2027.
- Restructuring: headcount reduced ~50%, manufacturing facility decommissioned by year-end 2025; luvelta deprioritized.
- Lead candidate STRO-004 (Tissue Factor ADC) IND expected 2H 2025; STRO-006 IND 2026; dual-payload ADC IND 2027.
- Astellas collaboration triggers $7.5M milestone from IND-enabling tox study for iADC program.
- Restructuring cost $21M in Q1; expects further significant costs in 2025 for wind-down of luvelta trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017025067061/0000950170-25-067061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017025067061/stro-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-067061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer